Alzamend Neuro (ALZN) Shares Outstanding (Diluted) (2021 - 2026)
Powered by 
Analysis
Alzamend Neuro (ALZN) Shares Outstanding (Diluted) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Dil.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn | 544.00 Mn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 255.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn | 106.00 Mn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | 66.03 Mn |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 138.28 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 148.70 Mn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | 3.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 3.34 Mn |
| Jan 31, 2026 | 3.80 Mn |
| Oct 31, 2025 | 3.38 Mn |
| Jul 31, 2025 | 2.11 Mn |
| Apr 30, 2025 | 450,799.00 |
| Jan 31, 2025 | 613,082.00 |
| Oct 31, 2024 | 392,407.00 |
| Jul 31, 2024 | 86,424.00 |
| Apr 30, 2024 | 75,173.00 |
| Jan 31, 2024 | 78,381.00 |
| Oct 31, 2023 | 72,930.00 |
| Jul 31, 2023 | 72,918.00 |
| Apr 30, 2023 | 72,235.00 |
| Jan 31, 2023 | 72,833.00 |
| Oct 31, 2022 | 72,213.00 |
| Jul 31, 2022 | 72,212.00 |
| Apr 30, 2022 | 65,999.00 |
| Jan 31, 2022 | 69,755.00 |
| Oct 31, 2021 | 69,231.00 |
| Jul 31, 2021 | 62,661.00 |